Cohera Medical Inc.03.01.17
Cohera Medical Inc., a developer of absorbable surgical adhesives and sealants, has hired John Wyatt as vice president of sales.
“We are thrilled to welcome John to the Cohera team,” said Patrick Daly, president and CEO of Cohera Medical. “John’s experience in the aesthetic medical device and biopharmaceutical industry will be pivotal to Cohera. With the only FDA-approved adhesive for internal use and with our excellent clinical outcomes, John is poised to grow the TissuGlu Surgical Adhesive business and help make drain-free tummy tucks standard of care. His wealth of knowledge in the space and his relationships with the key opinion leaders in plastic surgery, make John the right person to lead our sales team.”
Prior to Joining Cohera, Wyatt served in several senior leadership roles in the aesthetic space, where he has spent more than 19 years of his career. He recently worked for Kythera Biopharmaceuticals, a company owned by Allergan, focused on developing and launching Kybella, the only U.S. Food and Drug Administration (FDA)-approved injectable treatment that destroys fat cells under the chin to improve your profile. Additionally, Wyatt helped lead the sales team at Mentor Worldwide LLC, a Johnson & Johnson Company, launch numerous implantable mammary devices and capital equipment for lipoplasty surgery.
“This is an exciting time to join the Cohera team,” said Wyatt. “Both TissuGlu Surgical Adhesive and Cohera’s pipeline product, Sylys Surgical Sealant, have enormous potential to revolutionize surgical procedures for both surgeons and patients.”
Wyatt received his BBA from the University of Oklahoma, majoring in marketing with a minor in economics. He resides in Nashville, Tenn.
Cohera Medical Inc. develops and commercializes a line of surgical adhesives and sealants. Cohera Medical’s products are based on a chemical design that is resorbable, non-toxic, and easy-to-use. The Raleigh, N.C.-based company’s lead product, TissuGlu Surgical Adhesive, is indicated for use in the United States for the approximation of tissue planes in abdominoplasty procedures. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty, mastectomy, ventral hernia repair, decubitus and latissimus dorsi flap procedures. The company’s second product under development, Sylys Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes adhesives for surgical mesh fixation, meniscal repair and other orthopedic indications. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the FDA in the United States.
“We are thrilled to welcome John to the Cohera team,” said Patrick Daly, president and CEO of Cohera Medical. “John’s experience in the aesthetic medical device and biopharmaceutical industry will be pivotal to Cohera. With the only FDA-approved adhesive for internal use and with our excellent clinical outcomes, John is poised to grow the TissuGlu Surgical Adhesive business and help make drain-free tummy tucks standard of care. His wealth of knowledge in the space and his relationships with the key opinion leaders in plastic surgery, make John the right person to lead our sales team.”
Prior to Joining Cohera, Wyatt served in several senior leadership roles in the aesthetic space, where he has spent more than 19 years of his career. He recently worked for Kythera Biopharmaceuticals, a company owned by Allergan, focused on developing and launching Kybella, the only U.S. Food and Drug Administration (FDA)-approved injectable treatment that destroys fat cells under the chin to improve your profile. Additionally, Wyatt helped lead the sales team at Mentor Worldwide LLC, a Johnson & Johnson Company, launch numerous implantable mammary devices and capital equipment for lipoplasty surgery.
“This is an exciting time to join the Cohera team,” said Wyatt. “Both TissuGlu Surgical Adhesive and Cohera’s pipeline product, Sylys Surgical Sealant, have enormous potential to revolutionize surgical procedures for both surgeons and patients.”
Wyatt received his BBA from the University of Oklahoma, majoring in marketing with a minor in economics. He resides in Nashville, Tenn.
Cohera Medical Inc. develops and commercializes a line of surgical adhesives and sealants. Cohera Medical’s products are based on a chemical design that is resorbable, non-toxic, and easy-to-use. The Raleigh, N.C.-based company’s lead product, TissuGlu Surgical Adhesive, is indicated for use in the United States for the approximation of tissue planes in abdominoplasty procedures. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty, mastectomy, ventral hernia repair, decubitus and latissimus dorsi flap procedures. The company’s second product under development, Sylys Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes adhesives for surgical mesh fixation, meniscal repair and other orthopedic indications. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the FDA in the United States.
